The current financial score of Caris Life Sciences Inc is 7.38. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 263.71M, representing a year-over-year increase of 45.38%, while its net profit experienced a year-over-year increase of 99.88%.
The current valuation score of Caris Life Sciences Inc is 5.15. Its current P/E ratio is -11.19, which is -68.79% below the recent high of -3.49 and 0.00% above the recent low of -11.19.
The current earnings forecast score of Caris Life Sciences Inc is 8.33. The average price target is 27.00, with a high of 33.00 and a low of 22.00.
The current price momentum score of Caris Life Sciences Inc is 5.82. Currently, the stock price is trading between the resistance level at 33.98 and the support level at 25.22, making it suitable for range-bound swing trading.
The current institutional shareholding score of Caris Life Sciences Inc is 3.00. The latest institutional shareholding proportion is 38.87%, representing a quarter-over-quarter decrease of 30.07%. The largest institutional shareholder is Philippe Laffont, holding a total of 9.82M shares, representing 0.36% of shares outstanding, with 45.72% decrease in holdings.
The current risk assessment score of Caris Life Sciences Inc is 4.97. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.